All In Biotech

Investigational drug · Phase 2

itacitinib

Also called: INCB039110

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-Cell Malignancies, Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

54

Any phase or sponsor naming "itacitinib"

First trial start

2016

Dec 20, 2016

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "itacitinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • B-Cell Malignancies
  • Lung Cancer

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "itacitinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 70 on PubMed

Also in development for B-Cell Malignancies

  • EmavusertibCA-4948Phase 22 trials

    Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

  • parsaclisibINCB050465Phase 22 trials

    Incyte · Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma, B-Cell Malignancies

  • AZD5492Phase 21 trial

    AstraZeneca · B-cell Malignancies

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.